BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Quad elvitegravir/cobicistat/emtricitabine/tenofovir: Additional Phase II data

Additional data from the double-blind Phase II GS-US-236-0104 trial in 71 treatment-naïve patients with HIV RNA levels >=5,000 copies/mL showed that the proportion of patients who achieved HIV RNA levels <50 copies/mL at 48 weeks was 90% for once-daily Quad vs. 83% for Atripla emtricitabine/tenofovir/efavirenz. Data were presented at the Interscience Conference on Antimicrobial Agents...

Read the full 265 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >